News and views
Our magazine
Insights gives you all the news from the labs, hot topics, health tips and personal stories. Available as a free monthly email or twice-yearly magazine.
Sign up for more news and views"My proudest moments are when people say: 'Thank you for letting me take part in your study'."
Men volunteering to take part in clinical trials are vital for improving treatments, including improving our understanding of the effects of hormone therapy.
NICE decision on abiraterone could take away best hope for some men with incurable disease
BLOG: Abiraterone should continue to be available on the NHS and opened up to all men with newly diagnosed advanced prostated cancer, argues our policy manager Tim Windle, as the UK’s drug guidelines body is set to rule on the future of the treatment.
Hormone therapy shortage should only last a few months says drugs industry body
After we investigated complaints from men unable to get hold of the off-patent prostate cancer drug, bicalutamide, the British Generic Manufacturers' Association has told us problems with supply shouldn't last long.
Study finds early docetaxel and abiraterone equally effective
Prostate Cancer UK welcomes new data from the STAMPEDE trial that clarifies there is no difference in the benefits offered by both treatments for men newly diagnosed with advanced disease, but now we want the option of earlier abiraterone made available to all men.
New STAMPEDE trial results show earlier abiraterone could improve survival of men with advanced prostate cancer
Announced by researchers at a cancer conference in Chicago, the new findings show earlier and combined use of existing treatments can have a significant impact on advanced disease, but questions remain about its suitability for all men.
What a difference a year in research makes
BLOG: We're only 12 months into our ten-year strategy to tame prostate cancer, but that doesn't mean we haven't already made exciting progress. Our resident expert, Dr Ian Le Guillou, gives us his top ten biggest research breakthroughs (in no particular order) from 2016.
Testosterone 'floods and droughts' treatment shows early promise
A new type of treatment that alternately floods and starves the body of testosterone has shown good early results in men with advanced prostate cancer, according to new findings revealed today.
Behind the Headlines: Does hormone therapy really increase your risk of dementia?
Following reports in the press yesterday of a US study into androgen deprivation therapy – a commonly used treatment for men with prostate cancer in the UK – Prostate Cancer UK's Dr Iain Le Guilliou investigates whether there's any solid proof behind claims it could double the risk of dementia.
New link between testosterone and cancer cell aggression discovered
Prostate Cancer UK and the Movember Foundation reveals new opportunities for diagnosing and treating aggressive prostate cancer
Degarelix approved for men in England whose cancer has spread to the spine
Today’s approval of the hormone therapy, degarelix, by NICE expands on the decision made in 2014 to make it only available to those men who have already developed the symptoms of spinal cord compression. Now, men whose prostate cancer has spread to their spine and who could be at risk of this condition can also access this treatment.